Auris Medical has acquired Trasir Therapeutics, a startup developing technology that expands the delivery of RNA medicines to tissues beyond the liver. Going forward, Auris will sell or spin off its programs in hearing disorders and allergies and focus exclusively on RNA therapies.
It’s time to gear our machine learning tools to this data so that people with chronic illnesses and especially, complex chronic conditions can get the same kind of recommendations that they use every day to pick their movies or music or buy goods on the Internet.
Amgen is paying Kyowa Kirin $400 million to share in the development of a drug that could offer a new approach to treating atopic dermatitis, a form of eczema. The deal comes months after Japan-based Kyowa Kirin reported positive preliminary Phase 2 data for its antibody.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Doximity, the “LinkedIn for physicians,” is preparing for an IPO. In an unusual move, it’s setting aside a portion of its shares for some of its users.